bottom line updat model compani beat
rais incorpor detail confer call follow
call compani main concern stock continu
impact biosimilar humira competit europ although also wonder
compani impact reduc abil increas net price
humira us whether key pipelin asset abl help
reassur hear overal thing seem evolv line
compani guidanc earlier year even impact may
littl investor previous realiz primari focu
uptak skyrizi follow recent fda approv
upadacitinib path market fda action date month away
remain concern upadacitinib safeti profil would
surpris get fda easili gain rapid traction
market compani success could see
get construct stock meantim maintain
challeng biosimilar humira
valuat risk lower target price
maintain under-perform rate ep estim
chang tp
deriv blend dcf valuat use
wacc termin growth rate rel valuat base
ep main risk call includ stronger-than-
expect humira sale and/or success diversif busi away
humira dividend yield provid support
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
research-bas pharmaceut compani broad
sustain portfolio market-lead proprietari
pharmaceut biolog sold world-wide
price apr rate under-perform target price analyst vamil divan
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
blue sky valuat base greater sale
humira imbruvica market product compar
current base case assumpt blue sky valuat base
dcf driven wacc termin valu
grey sky valuat base lower sale humira
imbruvica market product compar current base
case assumpt grey sky valuat base dcf driven
wacc termin valu
notabl model updat along updat humira us ex-u sale
also lower estim synagi rais meaning skyrizi
given compani encourag commentari payer adopt potenti sale
ramp product expens assumpt gener
line compani guidanc remain guidanc oper
margin current forecast midpoint new ep
guidanc rang compani expect deliv ep growth half
come gross margin expans turn driven roll-off
humira royalti payment base estim
follow-up
opportun speak member team follow
confer call gain addit clariti dynam around certain product
well bake updat expect around fy
summar compani answer question
 clarifi humira outlook outsid us
eros ex-u sale guidanc oper basi
impact currenc make report basi
guidanc includ impact fx oper declin
also see impact declin less sinc
alreadi saw biosimilar impact last year
 latest expect humira eros outsid us next year beyond
base sale subject biosimilar competit
base face biosimilar
quantifi exactli much year insignific countri
go
would expect similar step term price eros
market alreadi biosimilar
see step newli competit market
provid color approach
single-digit fall mention previous
price impact comment futur year
 drove sequenti declin us
modestli sequenti
mainli due medicar donut hole reset occur cover larger
percentag donut hole prior year vs
also less posit price impact year vs last year price increas year
final saw unquantifi benefit chang tablet
see
tablet flat price oppos linear price capsul
patient impact extrem patient saw
price go
overal provid compani littl benefit
 two formul imbruvica tablet capsul
benefit take one pill tablet oppos capsul
 gener file formul imbruvica
ye would expect
composit matter expir late pediatr may later ip
number patent go includ tablet capsul
 tell us cash charg continu consider relat
recent approv skyrizi
transact requir establish conting liabil risk adjust present valu
quarter liabil revalu reflect studi readout time valu money etc
non-cash adjust book must adjust approv
small adjust meaning one given size product
record adjust
howev royalti payment impact oper cash outflow
balanc sheet
 coverag juli fulli final
convers payer beforehand
need final approv label final high degre confid metric
laid call achiev
think skyrizi upadacitinib strong formulari access
similar humira access-wis step-edit wise
gener fail humira get anoth prefer drug
 plan big updat like saw
plan strateg review right
updat investor commun relev inform
plan process may/june/juli time-frame
 impact potenti regulatori chang rebat discount term number
product formulari etc
think would affect formulari access
formulari want desir drug formulari
us million except per share valu
sale
net interest incom
us million unless otherwis state
fx impact sale
us million unless otherwis state
us million unless otherwis state
pipelin total sale
us million unless otherwis state
product sold ex-amort
tax earn
average share outstand
dilut ep oper
charl martineau pm univers toronto compani mention price
